Keyword Suggestion
Domain Informations
Coherus.com lookup results from whois.godaddy.com server:
- Domain created: 2012-04-18T18:09:52Z
- Domain updated: 2022-09-11T21:40:17Z
- Domain expires: 2026-04-18T18:09:52Z 1 Year, 363 Days left
- Website age: 12 Years, 1 Day
- Registrar Domain ID: 1714336951_DOMAIN_COM-VRSN
- Registrar Url: http://www.godaddy.com
- Registrar WHOIS Server: whois.godaddy.com
- Registrar Abuse Contact Email: [email protected]
- Registrar Abuse Contact Phone: 480-624-2505
- Name server:
- CLARK.NS.CLOUDFLARE.COM
- DORTHY.NS.CLOUDFLARE.COM
Network
- inetnum : 141.193.213.0 - 141.193.213.255
- name : WPENG
- handle : NET-141-193-213-0-1
- status : Direct Allocation
- created : 2020-03-20
- changed : 2020-07-14
Owner
- organization : WPEngine, Inc.
- handle : WPENG
- address : Array,Austin,TX,78701,US
Technical support
- handle : ADMIN7400-ARIN
- name : Admin
- phone : +1-877-973-6446
- email : [email protected]
Abuse
- handle : ABUSE7875-ARIN
- name : Abuse
- phone : +1-512-273-3906
- email : [email protected]
Domain Provider | Number Of Domains |
---|---|
godaddy.com | 286730 |
namecheap.com | 101387 |
networksolutions.com | 69118 |
tucows.com | 52617 |
publicdomainregistry.com | 39120 |
whois.godaddy.com | 32793 |
enomdomains.com | 23825 |
namesilo.com | 21429 |
domains.google.com | 21384 |
cloudflare.com | 20573 |
gmo.jp | 18110 |
name.com | 17601 |
fastdomain.com | 14708 |
register.com | 13495 |
net.cn | 12481 |
ionos.com | 12416 |
ovh.com | 12416 |
gandi.net | 12305 |
registrar.amazon.com | 12111 |
Host Informations
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
Site Inspections
Port Scanner (IP: 141.193.213.11)
Spam Check (IP: 141.193.213.11)
Email address with coherus.com
Recent Searched Sites
› Ssoft.su (43 seconds ago) / RU
› Celestron.com (13 seconds ago) / CA
› Exam.siiibtorsh.com (52 seconds ago) / IR
› Kimet.fi (53 seconds ago) / US
› Basketball-database.com (33 seconds ago) / NL
› Threevalleysradio.com (43 seconds ago) / GB
› Instaon.io (1 seconds ago) / US
› Mijnrijbewijs.eu (18 seconds ago) / NL
› Coherus.com (0 seconds ago) / US
› Friendlysonsnyc.com (8 seconds ago) / US
› Metrozemin.com (0 seconds ago) / TR
› Esthetique-osaka.com (18 seconds ago) / JP
› Fireandsteel.ca (12 seconds ago) / CA
› Greenvillenc.gov (3 mins ago) / US
› Healthnow.ph (53 seconds ago) / US
› Thetimes.co.uk (29 seconds ago) / IE
› Locfederal.branch-locations.com (8 seconds ago) / US
› Purmalis.ru (18 seconds ago) / RU
› Coviamg.com (16 seconds ago) / US
› Drqidwai.com.au (1 mins ago) / US
Websites Listing
We found Websites Listing below when search with coherus.com on Search Engine
Coherus
The current areas of focus of Coherus are to promote health-related programs of 501(c) 3 organizations, certain charitable events in support of community health and health education, wellness, scholarships or supporting the education of students to support programmatic activities and scholarships of 501(c) 3 organizations, including hospital foundations.
Grants.coherus.comHighlights | Coherus BioSciences, Inc.
The Board of Directors of Coherus BioSciences, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the ...
Investors.coherus.cominvestors.coherus.com
Investors.coherus.com
Investors.coherus.comCOVERAGE HOME - Coherus COMPLETE
Access to Commercial, Medicare, Medicaid, or other Government Insurance Coverage Begins Here
Coheruscomplete.comAbout Coherus - UDENYCA®
At Coherus, we manufacture UDENYCA® with a commitment to high quality, not high cost. Our promise. To offer those in need, whose viability depends on it—patients, healthcare professionals, institutions, and payers—the opportunity to choose the healthcare that will benefit patients the most. Coherus has brought to market a new standard of competition, embracing change and …
Udenyca.comCoherus BioSciences Announces New Employment Inducement …
2022-06-23 · Coherus BioSciences, Inc., announced that effective June 16, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 409,000 shares of the common stock of the Company to 16 newly hired employees with a per share exercise price of $5.86, the closing trading price on the grant date.
Biospace.comCoherus and Junshi Biosciences Receive Complete Response Letter …
2022-05-02 · About Coherus BioSciences. Coherus is a commercial stage biopharmaceutical company building a leading immuno-oncology franchise funded with cash generated by its commercial biosimilar business. In 2021, Coherus in-licensed toripalimab, an anti-PD-1 antibody, in the United States and Canada. Coherus plans to resubmit a BLA for toripalimab for ...
Investors.coherus.comCoherus BioSciences Announces New Employment Inducement
2022-06-22 · The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the Company’s board of directors in June 2016 under ...
Globenewswire.comSenior Scientist/Principal Scientist in the Molecular Interactions ...
2021-10-19 · E-mail: [email protected]. Beginning July 19, 2021, Coherus BioSciences requires all new hires to be fully vaccinated against COVID-19 as of their start date. This requirement is a condition of employment at Coherus BioSciences, and it applies regardless of whether the position is located at a Coherus BioSciences facility or is fully remote. If ...
Ziprecruiter.comCoherus BioSciences Announces New Employment Inducement …
2022-05-05 · The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the Company’s board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.
Stocktitan.netCoherus Biosciences Terminates Deal With Innovent for Avastin …
2022-05-06 · In Coherus Biosciences' earnings conference call for the first quarter (Q1) of 2022, the company announced it has discontinued development of a bevacizumab biosimilar candidate (CHS-305; IBI-305; Byvasda). Coherus entered into a license agreement with Innovent Biologics for the candidate in January 2020. Under the partnership, Coherus was to have the …
Centerforbiosimilars.comCoherus BioSciences Company Profile - Craft
2022-04-27 · Coherus BioSciences has 310 employees across 2 locations and $475.82 M in annual revenue in FY 2020. See insights on Coherus BioSciences including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.
Craft.coCoherus Biosciences, Inc. in Oklahoma City, OK | Company Info
Coherus Biosciences, Inc. is an Oklahoma Foreign For-Profit Business Corporation filed On November 12, 2020. The company's filing status is listed as In Existence and its File Number is 2312891530. The Registered Agent on file for this company is CT Corporation System and is located at 1833 S Morgan Rd, Oklahoma City, OK 73128.
Bizapedia.comCoherus BioSciences hiring Manager/Senior Manager, Purchasing ...
Beginning July 19, 2021, Coherus BioSciences requires all new hires to be fully vaccinated against COVID-19 as of their start date. This requirement is a …
Linkedin.comCoherus BioSciences hiring Product Development Internship in
Beginning July 19, 2021, Coherus BioSciences requires all new hires to be fully vaccinated against COVID-19 as of their start date. This requirement is a …
Linkedin.comCoherus BioSciences (CHRS) Expected to Beat Earnings Estimates: …
2020-10-29 · Coherus BioSciences (CHRS) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2020. This widely-known consensus outlook gives a good sense of the
Microsmallcap.comCoherus BioSciences, Inc. : UBS is neutraal gestemd over het aandeel
2022-06-14 · Het onderzoek van UBS bevestigt het advies voor aandeel en blijft Neutraal. | 26 juni 2022
Nl.marketscreener.comCoherus BioSciences (CHRS) May Report Negative Earnings: Know …
2022-04-28 · For the last reported quarter, it was expected that Coherus BioSciences would post a loss of $0.61 per share when it actually produced a loss of …
Zacks.comJunshi Biosciences and Coherus Receive Complete Response Letter …
2022-05-02 · About Coherus BioSciences Coherus is a commercial stage biopharmaceutical company building a leading immuno-oncology franchise funded with cash generated by its commercial biosimilar business. In 2021, Coherus in-licensed toripalimab, an anti-PD-1 antibody, in the United States and Canada. Coherus plans to resubmit a BLA for toripalimab for the …
Financialpost.comCoherus BioSciences Oncology Territory Manager Salaries in Sabhā
Average salary for Coherus BioSciences Oncology Territory Manager in Sabhā: $175,000. Based on 1 salaries posted anonymously by Coherus BioSciences Oncology Territory Manager employees in Sabhā.
Glassdoor.com
Domains Expiration Date Updated
Site | Provider | Expiration Date |
---|---|---|
dcm-inc.com | namecheap.com | -1 Years, -334 Days |
g20ys.org | nic.ru | -1 Years, -203 Days |
radeecal.in | publicdomainregistry.com | -1 Years, -251 Days |
flagsapi.com | porkbun.com | -1 Years, -139 Days |
freefollower.net | namesilo.com | -1 Years, -136 Days |
rodnik-altaya.com | nic.ru | -1 Years, -310 Days |
hindichristiansongs.in | rediff.co.in | -2 Years, -4 Days |
socrata.com | registrar.amazon.com | -1 Years, -344 Days |
igorvitale.org | we.register.it | -1 Years, -322 Days |
gherf.org | domain.com | -1 Years, -288 Days |